Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Nabeel M. Bardeesy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3867-0416; OpenAlex author ID A5108207076. Sources: funder_awards.

Their work

Papers
39 (first author 6, last author 8)
Trials
0
Grants
1
Labs led
1
Collaborators
162
Papers, trials and grants by year

2008: 1 grant · 2009: none · 2010: none · 2011: 2 papers · 2012: 2 papers · 2013: 4 papers · 2014: 4 papers · 2015: 5 papers · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers

Papers 39

  1. Genetics and biology of pancreatic ductal adenocarcinoma. Co-author DOI 10.1101/gad.351863.124↗
  2. Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment. Co-author DOI 10.1158/0008-5472.can-24-3384↗
  3. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216713↗
  4. Illuminating the path to pancreatic cancer. First author DOI 10.1038/s41422-024-00982-9↗
  5. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  6. Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer. Co-author DOI 10.1080/15384101.2023.2278945↗
  7. KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential. Last author DOI 10.1158/1078-0432.ccr-23-2221↗
  8. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2022.04.014↗
  9. Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS. Co-author DOI 10.3390/cancers14092153↗
  10. ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancer Co-author DOI 10.1101/2020.05.23.112839↗
  11. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
  12. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41379-018-0196-2↗
  13. Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer. Co-author DOI 10.7554/elife.45313↗
  14. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  15. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Co-author DOI 10.1242/dmm.034793↗
  16. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  17. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. First author DOI 10.1038/ctg.2017.3↗
  18. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Co-author DOI 10.1371/journal.pone.0182855↗
  19. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Co-author DOI 10.18632/oncotarget.20833↗
  20. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-016-3108-0↗
  21. SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Co-author DOI 10.1016/j.cell.2016.04.033↗
  22. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗
  23. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Last author DOI 10.1038/nature14587↗
  24. Gene signatures from pancreatic cancer tumor and stromal cells predict disease outcome. First author DOI 10.1038/ng.3408↗
  25. Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Co-author DOI 10.1093/carcin/bgv058↗
  26. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-14-1591↗
  27. Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. First author DOI 10.1158/2159-8290.cd-15-0671↗
  28. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.09.050↗
  29. Pancreatic adenocarcinoma. Last author DOI 10.1056/nejmc1412266↗
  30. Pancreatic adenocarcinoma. Last author DOI 10.1056/nejmra1404198↗
  31. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Co-author DOI 10.1073/pnas.1411679111↗
  32. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Co-author DOI 10.1038/nature12040↗
  33. Macrophages in pancreatic cancer: starting things off on the wrong track. Last author DOI 10.1083/jcb.201307066↗
  34. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. Last author DOI 10.1172/jci64535↗
  35. Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Co-author DOI 10.1593/neo.13276↗
  36. Ready, set, go: the EGF receptor at the pancreatic cancer starting line. First author DOI 10.1016/j.ccr.2012.08.019↗
  37. TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. Last author DOI 10.1158/0008-5472.can-12-0634↗
  38. Uncapping NF-κB activity in pancreatic cancer. First author DOI 10.1038/emboj.2010.324↗
  39. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Co-author DOI 10.1158/2159-8290.cd-11-0031↗

Grants 1

  1. Molecular Markers of Drug Sensitivity in Pancreatic Cancer AWARD pancan:2008-nabeel-bardeesy-phd-molecular-markers-of-drug-sensitivity-in

Closest collaborators

The 25 strongest of 162 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vikram Deshpande · 12 shared papers, 2012–2024 · strength 0.83
  2. Hiroyuki Kato · 2 shared papers, 2023–2024 · strength 0.76
  3. David Tsai Ting · 5 shared papers, 2016–2024 · strength 0.49
  4. Anirban Maitra · 3 shared papers, 2014–2025 · strength 0.47
  5. Ronald Anthony Depinho · 4 shared papers, 2011–2025 · strength 0.38
  6. Rushika Miriam Perera · 6 shared papers, 2012–2019 · strength 0.37
  7. Haoqiang Ying · 3 shared papers, 2011–2025 · strength 0.35
  8. Alec C. Kimmelman · 3 shared papers, 2011–2025 · strength 0.35
  9. Peter D. Caravan · 3 shared papers, 2018–2025 · strength 0.35
  10. Kenneth K. Tanabe · 3 shared papers, 2018–2025 · strength 0.35
  11. Raghu Kalluri · 1 shared paper, 2025 · strength 0.30
  12. Cristina R. Ferrone · 5 shared papers, 2013–2020 · strength 0.28
  13. Veronica Clavijo Jordan · 2 shared papers, 2020–2025 · strength 0.27
  14. Motaz Qadan · 2 shared papers, 2020–2025 · strength 0.27
  15. Carlos F. Fernandez-del Castillo · 4 shared papers, 2016–2019 · strength 0.25
  16. Filippos Kottakis · 2 shared papers, 2015–2023 · strength 0.25
  17. Theodoros P. Michelakos · 2 shared papers, 2020–2024 · strength 0.25
  18. Theodore Sunki Hong · 3 shared papers, 2014–2019 · strength 0.23
  19. Yusuke Mizukami · 3 shared papers, 2013–2017 · strength 0.22
  20. Turan Tufan · 2 shared papers, 2020–2022 · strength 0.21
  21. Mazhar Adli · 2 shared papers, 2020–2022 · strength 0.21
  22. Todd W. Bauer · 2 shared papers, 2020–2022 · strength 0.21
  23. Sarbajeet Nagdas · 2 shared papers, 2020–2022 · strength 0.21
  24. Xavier Deschênes‐Simard · 2 shared papers, 2013–2023 · strength 0.20
  25. David P. Ryan · 3 shared papers, 2014–2017 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.